The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of
cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer
(NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However …

Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to
treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal
growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer …

Acquired T790 M mutation is the commonest cause of resistance for advanced non-small
cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant patients who had …

EGFR mutations account for the majority of druggable targets in lung adenocarcinoma. Over
the past decades the optimization of EGFR inhibitors revolutionized the treatment options for …

Epidermal growth factor receptor (EGFR), a member of the HER family, is closely related to
the development of multiple cancers. Herein, we report the discovery of small molecule …